Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brigitta Derendinger

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
The Lancet. Global Health|April 7, 2024
Point-of-care C-reactive protein and Xpert MTB/RIF Ultra for tuberculosis screening and diagnosis in unselected antiretroviral therapy initiators: a prospective, cross-sectional, diagnostic accuracy studyByron W P Reeve, Gcobisa Ndlangalavu, Hridesh Mishra, et al.
American Journal of Respiratory and Critical Care Medicine|February 17, 2022
An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study)Aliasgar Esmail, Suzette Oelofse, Carl Lombard, et al.
The Lancet. Microbe|November 6, 2023
Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort studyBrigitta Derendinger, Anzaan Dippenaar, Margaretha de Vos, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
The Lancet. Global Health|April 7, 2024
Point-of-care C-reactive protein and Xpert MTB/RIF Ultra for tuberculosis screening and diagnosis in unselected antiretroviral therapy initiators: a prospective, cross-sectional, diagnostic accuracy studyByron W P Reeve, Gcobisa Ndlangalavu, Hridesh Mishra, et al.
American Journal of Respiratory and Critical Care Medicine|February 17, 2022
An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study)Aliasgar Esmail, Suzette Oelofse, Carl Lombard, et al.
The Lancet. Microbe|November 6, 2023
Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort studyBrigitta Derendinger, Anzaan Dippenaar, Margaretha de Vos, et al.
Pageof 3